Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals

NCT03603808 is registered in ClinicalTrials.gov with AIDS Malignancy Consortium as lead sponsor.

NCT NCT03603808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03603808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
Lead sponsor
AIDS Malignancy Consortium
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2018
Completion date
June 17, 2025
Enrollment
44 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

anal intraepithelial neoplasia, high grade squamous intraepithelial neoplasia, hiv positivity, human papillomavirus-16 positive, human papillomavirus-18 positive